eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 21

Clinical evaluation of short-term efficacy of pimecrolimus in the treatment of children suffering from atopic dermatitis

Ryszard Kurzawa
Małgorzata Wanat-Krzak
Krzysztof Pisiewicz
Urszula Jędrys-Kłucjasz
Adam Wójcik

PDiA 2004; XXI, 5: 211–219
Online publish date: 2004/10/26
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Introduction: Atopic dermatitis (AD) is one of the most common skin diseases in children. Treatment of AD is often a big problem both for patients and physicians, and requires their close cooperation. The main anti-inflammatory treatment of AD is based on topical glucocorticosteroids, which are associated with a high risk of side effects. Calcineurin inhibitors are new topical medications available for the treatment of AD patients.
Aim: The aim of this study was to assess the short-term effectiveness of pimecrolimus 1% cream in the treatment of atopic dermatitis in children.
Material and methods: The study was performed in a group of 40 children with mild to moderate atopic dermatitis. Pimecrolimus 1% cream was applied twice a day on the affected skin. At every visit the extent and severity of skin changes were evaluated according to EASI. The intensity of pruritis and sleep disturbances were evaluated on a 10-point scale.
Results: The baseline of the study was mean EASI value of 12.0 and after 3 days of treatment EASI value decreased to 5.9. There was also an improvement in pruritis intensity from 6.2 to 3.2 and in sleep disturbances from 4.5 to 2.1. The differences were statistically significant.
Conclusions: The results show that pimecrolimus 1% cream is highly effective in the treatment of AD children. There was a statically significant improvement in the clinical condition of patients and a reduction in severity of symptoms (pruritis and sleep disturbances) after 3 days of treatment.

atopic dermatitis, children, treatment, calcineurin inhibitors

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe